Bio-Rad Laboratories, Inc. (BIO)
| Market Cap | 18.19B |
| Revenue (ttm) | 2.70B |
| Net Income (ttm) | 4.10B |
| Shares Out | 29.82M |
| EPS (ttm) | 135.87 |
| PE Ratio | 4.47 |
| Forward PE | 47.62 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $608.01 |
| Previous Close | $602.17 |
| Change ($) | 5.84 |
| Change (%) | 0.97% |
| Day's Open | 607.05 |
| Day's Range | 603.68 - 615.32 |
| Day's Volume | 137,872 |
| 52-Week Range | 425.43 - 689.00 |
Bio-Rad's (BIO) first-quarter revenues improved year over year on robust growth in Life Science and Clinical Diagnostics segments.
Bio-Rad (BIO) delivered earnings and revenue surprises of 108.40% and 9.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the f...
Growing demand for Polymerase Chain Reaction and Droplet Digital PCR products is expected to have contributed to BioRad's (BIO) Q1 growth.
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first...
In my opinion, investors could be interested in the three stocks listed below, as they meet the following criteria:
Investors remain optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies and robust testing portfolio.
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?
Benjamin Graham, the father of value investing, recommended to stick to stocks that have a current ratio of more than 2 and more working capital than long-term debt.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, Presi...
Non-operating income not only overstates GAAP net income but could negatively impact Bio-Rad's ability to obtain additional financing.
Bio-Rad to Participate in Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, Presi...
Does Bio-Rad Laboratories (BIO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.
Bio-Rad (BIO) delivered earnings and revenue surprises of 29.35% and 15.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Bio-Rad Laboratories (NYSE:BIO) moved higher by 2.0% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 72.84% year over year to $4.0...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the f...
Bio-Rad Laboratories (NYSE:BIO) unveils its next round of earnings this Thursday, February 11. Get prepared with Benzinga's ultimate preview for Bio-Rad Laboratories's Q4 earnings.
Bio-Rad (BIO) Q4 earnings are expected to have benefited from strong sales, particularly within core PCR products, Droplet Digital PCR and Process Media.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the fourt...
If you pick securities whose earnings return is more than twice that of the 20-year high-quality market corporate bonds, you could increase your probability to unearth value opportunities, in my opinion...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, Presi...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today its outlook through 2023, w...
Investors continue to be optimistic about Bio-Rad (BIO) on robust growth of the Life Science segment and a solid testing portfolio.
These are the healthcare stocks with the best value, fastest growth, and most momentum for December 2020.
Is (BIO) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for November 13th
Value focused investors may want to consider the following stocks, since their share prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-based discounted cash flow ...
As of late, it has definitely been a great time to be an investor in Bio-Rad Laboratories (BIO).
Bio-Rad (BIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bio-Rad's (BIO) third-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.
Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q3 2020 Results - Earnings Call Transcript
Bio-Rad (BIO) delivered earnings and revenue surprises of 62.16% and 14.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Bio-Rad Laboratories (NYSE:BIO) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 86.34% year over year to $3.00, which beat th...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the t...
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in r...
Bio-Rad (BIO) Q3 earnings are expected to have benefited from strong sales particularly within core PCR products, Droplet Digital PCR and Process Media.
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Gains 16.2% Since September, Bullish Outlook Remains Strong
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the third...
Bio-Rad (BIO) is optimistic about maintaining robust testing portfolio along with strength in its Life Sciences business.
With four potential Covid-19 vaccine candidates from Moderna Inc. (NASDAQ:MRNA), Pfizer Inc. (NYSE:PFE), AstraZeneca PLC (NYSE:AZN) and Johnson & Johnson (NYSE:JNJ) now in late-stage human trials, and m...
About BIO
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research tech... [Read more...]
| Industry Medical Devices | Founded 1952 |
| CEO Norman Schwartz | Employees 7,800 |
| Stock Exchange NYSE | Ticker Symbol BIO |
Financial Performance
In 2020, BIO's revenue was $2.55 billion, an increase of 10.12% compared to the previous year's $2.31 billion. Earnings were $3.81 billion, an increase of 116.43%.
Analyst Forecasts
According to 4 analysts, the average rating for BIO stock is "Buy." The 12-month stock price forecast is 755.00, which is an increase of 24.18% from the latest price.